Effect of acute and chronic olanzapine treatment on phencyclidine-induced behavioral sensitization in rats with neonatal dopamine loss

Pharmacology Biochemistry and Behavior

Volumn 78, Issue 1, 2004, Pages 47-56

  Moy, Sheryl S ^a   Fernandes, Alda ^c   Qian, Ying ^c   Rotella, Dana J ^c   Kostrewa, Richard M ^b   Breese, George R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b East Tennessee State University   (United States)

^c NONE

Author keywords

Acute haloperidol; Acute olanzapine; Behavioral sensitization; Chronic haloperidol; Chronic olanzapine; Ketanserin; Neonate 6 hydroxydopamine lesion; Phencyclidine

Indexed keywords

CLOZAPINE; HALOPERIDOL; KETANSERIN; OLANZAPINE; PHENCYCLIDINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SENSITIZATION;

ANIMALS; ANIMALS, NEWBORN; BENZODIAZEPINES; DOPAMINE; DRUG INTERACTIONS; FEMALE; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 2442648704     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.02.013     Document Type: Article

References (54)

1. Abekawa T., Honda M., Ito K., Inoue T., Koyama T. Effect of MS-153 on the development of behavioral sensitization to locomotion- and ataxia-inducing effects of phencyclidine. Psychopharmacology. 160:2002;122-131
2. Abekawa T., Honda M., Ito K., Inoue T., Koyama T. Effect of MS-153 on the development of behavioral sensitization to stereotypy-inducing effect of phencyclidine. Brain Res. 926:2002;176-180
3. Bakshi V.P., Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology. 122:1995;198-201
4. Baldessarini R.J. Drugs and the treatment of psychiatric disorders. Gilman A.G., Rall T.W., Nies A.S., Taylor P. Goodman and Gilman's the pharmacological basis of therapeutics. 1990;383-435 Pergamon, Elmsford (NY)
5. Berger T.W., Kaul S., Stricker E.M., Zigmond M.J. Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res. 336:1985;354-358
6. Breese G.R., Baumeister A.A., McCown T.J., Emerick S.G., Frye G.D., Crotty K., et al. Behavioral differences between neonatal and young adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J. Pharmacol. Exp. Ther. 231:1984;343-354
7. Breese G.R., Napier T.C., Mueller R.A. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats. J. Pharmacol. Exp. Ther. 234:1985;447-455
8. Breese G.R., Knapp D.J., Moy S.S. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci. Biobehav. Rev. 26:2002;441-455
9. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96
10. 1-adrenergic receptors in vitro. Schizophr. Res. 37:1999;107-122
11. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm. 75:1989;221-226
12. Clark M., Johnson B.G., Wright R.A., Monn J.A., Schoepp D.D. Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine- sensitized rats. Pharmacol. Biochem. Behav. 73:2002;339-346
13. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology. 120:1995;67-74
14. Criswell H.E., Mueller R.A., Breese G.R. Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors. Eur. J. Pharmacol. 159:1989;141-147
15. 1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats. J. Neurosci. 9:1989;125-133
16. 1-dopamine receptor sensitization in neonatal 6-OHDA-lesioned rats is blocked by an NMDA antagonist. Brain Res. 512:1990;284-290
17. Criswell H.E., Johnson K.B., Mueller R.A., Breese G.R. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J. Pharmacol. Exp. Ther. 265:1993;1001-1010
18. Geyer M.A., Swerdlow N.R., Mansbach R.S., Braff D.L. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res. Bull. 25:1990;485-498
19. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 156:2001;117-154
20. Gleason S.D., Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology. 129:1997;79-84
21. Higgins G.A., Enderlin M., Haman M., Fletcher P.J. The 5-HT(2A) receptor antagonist M100, 907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism. Psychopharmacology. 170:2003;309-319
22. Honack D., Loscher W. Sex differences in NMDA receptor mediated responses in rats. Brain Res. 620:1993;167-170
23. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatr. 148:1991;1301-1308
24. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225
25. Kostrzewa R.M., Reader T.A., Descarries L. Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J. Neurochem. 70:1998;889-898
26. Krebs-Thomson K., Lehmann-Masten V., Naiem S., Paulus M.P., Geyer M.A. Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin. Eur. J. Pharmacol. 343:1998;135-143
27. 2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology. 13:1995;139-150
28. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19
29. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 17:1997;205-229
30. Linn G.S., Negi S.S., Gerum S.V., Javitt D.C. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology. 169(3-4):2003;234-239
31. Loscher W., Honack D. The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol. 215:1992;199-208
32. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiatry. 42:1997;664-668
33. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150
34. Martin P., Waters N., Waters S., Carlsson A., Carlsson M.L. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur. J. Pharmacol. 335:1997;107-116
35. 2A receptors. Eur. J. Pharmacol. 280:1995;R9-R11
36. Moghaddam B., Adams B. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352
37. Moy S.S., Breese G.R. Phencyclidine supersensitivity in rats with neonatal dopamine loss. Psychopharmacology. 161:2002;255-262
38. Moy S.S., Breese G.R., Eckerman D.A. Altered activity patterns following neonatal 6-hydroxydopamine lesions to dopaminergic neurons: effect of SKF-38393. Brain Res. 645:1994;49-60
39. 1-dopamine receptors in rats with neonatal dopamine loss. Neuropsychopharmacology. 25:2001;224-233
40. Nabeshima T., Yamada K., Yamaguchi K., Hiramatsu M., Furukawa H., Kameyama T. Effect of lesions in the striatum, nucleus accumbens and medial raphe on phencyclidine-induced stereotyped behaviors and hyperactivity in rats. Eur. J. Pharmacol. 91:1983;455-462
41. Ninan I., Jardemark K.E., Wang R.Y. Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex. Neuropharmacology. 44:2003;462-472
42. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33:1999;523-533
43. Parwani A., Duncan E.J., Bartlett E., Madonick S.H., Efferen T.R., Rajan R., et al. Impaired prepulse inhibition of acoustic startle in schizophrenia. Biol. Psychiatry. 47:2000;662-669
44. 2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiograpic study. Brain Res. 606:1993;273-285
45. Sams-Dodd F. A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology. 18:1998;293-304
46. Schallert T., Petrie B.F., Wishaw I.Q. Neonatal dopamine depletion: spared and unspared sensorimotor and attentional disorders and effects of further depletion in adulthood. Psychobiology. 17:1989;386-396
47. Schotte A., Jannssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73
48. Schwarzkopf S.B., Mitra T., Bruno J.P. Sensory gating in rats depleted of dopamine as neonates: potential relevance to findings in schizophrenic patients. Biol. Psychiatry. 31:1992;759-773
49. Schwarzkopf S.B., Bruno J.P., Mitra T., Ison J.R. Effects of haloperidol and SCH 23390 on acoustic startle in animals depleted of dopamine as neonates: implications for neuropsychiatric syndromes. Psychopharmacology. 123:1996;258-266
50. Swanson C.J., Schoepp D.D. The group II metabotropic glutamate receptor agonist (-)-2-Oxa-4-aminobicyclo[3.1.0.]hexane-4, 6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats. J. Pharmacol. Exp. Ther. 303:2002;919-927
51. Swerdlow N.R., Bakshi V., Geyer M. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther. 279:1996;1290-1299
52. Wang R.Y., Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology. 19:1998;74-85
53. Xu X., Domino E.F. Genetic differences in the locomotor response to single and daily doses of phencyclidine in inbred mouse strains. Behav. Pharmacol. 5:1994;623-629
54. 2A, and muscarinic receptors. Psychopharmacology. 141:1999;267-278